IMPRINT pump priming project N°4: Using in vitro mycobacterial growth inhibition assays as a tool to assess functional immune responses induced by VPM1002 vaccination in infants

January 18, 2018




Tuberculosis (TB) is a disease caused by a germ that can affect the lungs and in severe cases, the blood and the brain. Almost one million children, mostly from the tropics, suffered from TB in the year 2015. A vaccine called BCG is used to prevent this disease. It is given to babies and is able to prevent severe forms of TB that involve the blood and the brain but does not provide adequate protection from the lung form which is the most common. New vaccines that are able to do a better job at preventing TB in babies are needed. VPM1002 is a vaccine that has been developed to work better than BCG. It has been tested in adults and babies and the results show that it is safe, however we need to know how well it is able to kill TB germs. This study aims to use a tool in the lab to show how well the new vaccine, VPM1002 works in babies from Uganda, an African country where TB is common.

Project lead:

Mr Simon Gwapa Kimuda

Associate Scientist

Immunomodulation and Vaccines

Medical Research Council/UVRI Uganda Research Unit on AIDS

Entebbe, Uganda

IMPRINT partners:

Prof. Alison Elliott, Medical Research Council/UVRI Uganda Research Unit on AIDS, Uganda

Prof. Gerhard Walzl, Stellenbosch University, South Africa

Dr Helen Fletcher, London School of Hygiene & Tropical Medicine, United Kingdom

Project duration: 12 months


You might also like to read

March 25, 2021

Presentation on the impact of COVID-19 on the health of newborns

Dr Chris Gale from Imperial College London provided new insights about the impact of COVID-19 on the health of neonates in a webinar organised by IMPRINT.